Pharmaxis is an Australian pharmaceutical research company focussed on inflammation and fibrosis with a portfolio of products at various stages of development and approval.

Established in 1998 and listed on the Australian Securities Exchange in 2003 (symbol PXS) the Company’s head office, manufacturing and research facilities are located in Sydney, Australia.

The Company’s product pipeline is founded on its expertise in the chemistry of amine oxidase inhibitors and includes Semicarbazide-Sensitive Amine Oxidase (SSAO) for Non- Alcoholic Steatohepatitis (NASH), diabetic retinopathy and other inflammatory diseases including kidney fibrosis and Chronic Obstructive Pulmonary Disease (COPD); and Lysyl Oxidase Inhibitors (LOX) targeting fibrotic diseases including NASH, pulmonary fibrosis, kidney fibrosis and some cancers.

Pharmaxis’ acknowledged expertise in amine oxide inhibitors has attracted interest from leading pharmaceutical companies looking to make acquisitions or partner in this rapidly expanding area of medical need. In May 2015, Boehringer Ingelheim acquired the Pharmaxis phase 1 investigational drug BI
1467335 (formerly known as PXS4728A
), to develop it for the treatment of the cardiometabolic liver-related condition NASH. A phase 2 clinical trial in NASH commenced in August 2017 triggering payment of a development milestone to Pharmaxis of approximately A$27 million. In September 2017, Boehringer announced it would proceed with a second indication BI 1467335, this time in Diabetic Retinopathy (DR). A phase 2a clinical trial will test the drug in in 100 patients with moderately severe to severe non-proliferative diabetic retinopathy.

Pharmaxis manufacturers and exports its approved products from a purpose built manufacturing facility in Sydney.

  • Bronchitol®, an inhaled dry powder for the treatment of cystic fibrosis, has been the subject of two large scale global clinical trials conducted by Pharmaxis. The product is approved and marketed in Europe, Russia and Australia and a third large multicentre clinical trial aiming to secure approval in the United States reported in June 2017. Outside Australia, Pharmaxis partners with a number of specialist  companies who have responsibility for their local approvals and ongoing commercialisation of Bronchitol. For more information visit the Bronchitol website.
  • Aridol® a lung function test to help diagnose asthma was also the subject of a clinical trial program run by Pharmaxis and is approved and sold in Europe, Australia and Asia. For more information visit the Aridol website.

The Senior Management  and Board of Directors have significant experience in drug discovery, clinical development, business development and pharmaceutical company management and marketing.